Following an exploration of potential regulatory pathways for cannabidiol (CBD) products by an internal Food and Drug Administration (FDA) working group, the FDA concluded on January 26, 2023, that a new regulatory pathway for CBD is needed to provide the regulatory oversight necessary to manage risk. The Agency is prepared to work with Congress on this issue.
Français